FDA Clearance Tracker · K254264
Sofia 2 SARS Antigen+ FIA; Sofia 2 Lyme FIA
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 4, 2026
Substantially Equivalent
Time to decision
248 days
Received Dec 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K254264
- Device name
- Sofia 2 SARS Antigen+ FIA; Sofia 2 Lyme FIA
- Applicant location
- San Diego, CA
- Received
- Dec 30, 2025
- Decided
- Sep 4, 2026
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3982
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QVF. The earliest in FDA's data is DEN220039, decided Mar 8, 2023.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K254264
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Ortho-Clinical Diagnostics, Inc. (QuidelOrtho)
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254262 · Decided Sep 4, 2026 · 248 days after receipt
Device type: Devices Detecting Influenza A, B, And C Virus Antigens (PSZ) · Laboratory Medicine & Pathology
K254295 · Decided Jul 10, 2026 · 191 days after receipt
Device type: Reagent, Borrelia Serological Reagent (LSR) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.